Saphenous Vein Graft Aneurysm after Drug-Eluting Stent Implantation: Treatment by Covered Stent.
Papadopoulos K, Avraamides P.
Case Rep Cardiol. 2021 Nov 5;2021:2360804. doi: 10.1155/2021/2360804. eCollection 2021.
Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis.
Yahagi K, Kolodgie FD, Otsuka F, Finn AV, Davis HR, Joner M, Virmani R.
Nat Rev Cardiol. 2016 Feb;13(2):79-98. doi: 10.1038/nrcardio.2015.164. Epub 2015 Oct 27.
Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial.
Fahrni G, Farah A, Engstrøm T, Galatius S, Eberli F, Rickenbacher P, Conen D, Mueller C, Pfister O, Twerenbold R, Coslovsky M, Cattaneo M, Kaiser C, Mangner N, Schuler G, Pfisterer M, Möbius-Winkler S, Jeger RV; BASKET‐SAVAGE‐Investigators*.
J Am Heart Assoc. 2020 Oct 20;9(20):e017434. doi: 10.1161/JAHA.120.017434. Epub 2020 Oct 9.
Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial.
Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schömig A, Kastrati A; Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts? (ISAR-CABG) Investigators.
Lancet. 2011 Sep 17;378(9796):1071-8. doi: 10.1016/S0140-6736(11)61255-5. Epub 2011 Aug 26.
Propensity score-matched analysis of coronary artery bypass grafting versus second-generation drug-eluting stents for triple-vessel disease.
Nishigawa K, Fukui T, Hagiya K, Tobaru T, Uemura K, Takanashi S.
Eur J Cardiothorac Surg. 2019 Jun 1;55(6):1152-1159. doi: 10.1093/ejcts/ezy415.
Sealing Intermediate Nonobstructive Coronary Saphenous Vein Graft Lesions With Drug-Eluting Stents as a New Approach to Reducing Cardiac Events: A Randomized Controlled Trial.
Rodés-Cabau J, Jolly SS, Cairns J, Mansour S, L'Allier PL, Teefy PJ, Graham JJ, Le May MR, Cantor WJ, Wood D, Balasubramanian K, DeLarochellière R, Dzavik V; VELETI II Investigators (Sealing Moderate Coronary Saphenous Vein Graft Lesions With Paclitaxel-Eluting Stents).
Circ Cardiovasc Interv. 2016 Nov;9(11):e004336. doi: 10.1161/CIRCINTERVENTIONS.116.004336.
Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K, Mehilli J, Byrne RA, Schulz S, Massberg S, Laugwitz KL, Vorpahl M, Seyfarth M, Kastrati A; ISAR-LEFT MAIN Study Investigators.
JACC Cardiovasc Interv. 2014 Jan;7(1):29-36. doi: 10.1016/j.jcin.2013.08.013. Epub 2013 Dec 11.
Saphenous Vein Graft Aneurysm 10 Years After Paclitaxel-Eluting Stent Implantation.
Tanaka A, Jabbour RJ, Giannini F, Latib A, Colombo A.
J Invasive Cardiol. 2017 May;29(5):E63.
Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
Chieffo A, Meliga E, Latib A, Park SJ, Onuma Y, Capranzano P, Valgimigli M, Jegere S, Makkar RR, Palacios IF, Kim YH, Buszman PE, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Capodanno D, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A.
JACC Cardiovasc Interv. 2012 Jul;5(7):718-27. doi: 10.1016/j.jcin.2012.03.022.
Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions: a critical appraisal.
Brilakis ES, Saeed B, Banerjee S.
J Interv Cardiol. 2008 Apr;21(2):151-7. doi: 10.1111/j.1540-8183.2007.00341.x. Epub 2008 Feb 28.
